Stock 4559 ZERIA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Zeria Pharmaceutical Co., Ltd.

Equities

4559

JP3428850006

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
2,119 JPY +1.00% Intraday chart for Zeria Pharmaceutical Co., Ltd. +3.01% +5.06%
Apr. 23 Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints CI
Feb. 16 Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024
Zeria Pharmaceutical's Attributable Profit Soars 48% in Fiscal Nine Months
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of the Year Ending March 31, 2023, Payable on December 1, 2022
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till May 12, 2023.
Zeria Pharmaceutical Co., Ltd. Announces Consolidated Earnings Guidance for the Six Months and Fiscal Year Ending March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4559 Stock
  4. News Zeria Pharmaceutical Co., Ltd.
  5. Other languages